| Field | Row 1 |
|---|---|
| adsh | 0001558370-25-006966 |
| cik | 1626971 |
| name | CORVUS PHARMACEUTICALS, INC. |
| sic | 2834 |
| countryba | US |
| stprba | CA |
| cityba | BURLINGAME |
| zipba | 94010 |
| bas1 | 863 MITTEN ROAD |
| bas2 | SUITE 102 |
| baph | (650) 900-4520 |
| countryma | US |
| stprma | CA |
| cityma | BURLINGAME |
| zipma | 94010 |
| mas1 | 863 MITTEN ROAD |
| mas2 | SUITE 102 |
| countryinc | US |
| stprinc | DE |
| ein | 464670809 |
| former | |
| changed | |
| afs | 4-NON |
| wksi | 0 |
| fye | 1231 |
| form | 10-Q |
| period | 20250331 |
| fy | 2025 |
| fp | Q1 |
| filed | 20250508 |
| accepted | 2025-05-08 16:06:00.0 |
| prevrpt | 0 |
| detail | 1 |
| instance | crvs-20250331x10q_htm.xml |
| nciks | 1 |
| aciks |
| Field Name | Field Description |
|---|---|
| adsh | Accession Number. The 20-character string formed from the 18-digit number assigned by the SEC to each EDGAR submission. |
| cik | Central Index Key (CIK). Ten digit number assigned by the SEC to each registrant that submits filings. |
| name | Name of registrant. This corresponds to the name of the legal entity as recorded in EDGAR as of the filing date. |
| sic | Standard Industrial Classification (SIC). Four digit code assigned by the SEC as of the filing date, indicating the registrant’s type of business. |
| countryba | The ISO 3166-1 country of the registrant's business address. |
| stprba | The state or province of the registrant’s business address, if field countryba is US or CA. |
| cityba | The city of the registrant's business address. |
| zipba | The zip code of the registrant’s business address. |
| bas1 | The first line of the street of the registrant’s business address. |
| bas2 | The second line of the street of the registrant’s business address. |
| baph | The phone number of the registrant’s business address. |
| countryma | The ISO 3166-1 country of the registrant's mailing address. |
| stprma | The state or province of the registrant’s mailing address, if field countryma is US or CA. |
| cityma | The city of the registrant's mailing address. |
| zipma | The zip code of the registrant’s mailing address. |
| mas1 | The first line of the street of the registrant’s mailing address. |
| mas2 | The second line of the street of the registrant’s mailing address. |
| countryinc | The ISO 3166-1 country of incorporation for the registrant. |
| stprinc | The state or province of incorporation for the registrant, if countryinc is US or CA. |
| ein | Employee Identification Number, 9 digit identification number assigned by the Internal Revenue Service to business entities operating in the United States. |
| former | Most recent former name of the registrant, if any. |
| changed | Date of change from the former name, if any. |
| afs | Filer status with the SEC at the time of submission: 1-LAF=Large Accelerated, 2-ACC=Accelerated, 3-SRA=Smaller Reporting Accelerated, 4-NON=Non-Accelerated, 5-SML=Smaller Reporting Filer, NULL=not assigned. |
| wksi | Well Known Seasoned Issuer (WKSI). An issuer that meets specific SEC requirements at some point during a 60-day period preceding the date the issuer satisfies its obligation to update its shelf registration statement. |
| fye | Fiscal Year End Date, rounded to nearest month-end. |
| form | The submission type of the registrant’s filing. |
| period | Balance Sheet Date, rounded to nearest month-end. |
| fy | Fiscal Year Focus (as defined in the EDGAR XBRL Guide Ch. 3.1.8). |
| fp | Fiscal Period Focus (as defined in the EDGAR XBRL Guide Ch. 3.1.8) within Fiscal Year. |
| filed | The date of the registrant’s filing with the Commission. |
| accepted | The acceptance date and time of the registrant’s filing with the Commission. |
| prevrpt | Previous Report – TRUE indicates that the submission information was subsequently amended. |
| detail | TRUE indicates that the XBRL submission contains quantitative disclosures within the footnotes and schedules at the required detail level (e.g., each amount). |
| instance | The name of the submitted XBRL Instance Document. The name often begins with the company ticker symbol. |
| nciks | Number of Central Index Keys (CIK) of registrants (i.e., business units) included in the consolidating entity’s submitted filing. |
| aciks | Additional CIKs of co-registrants included in a consolidating entity’s EDGAR submission, separated by spaces. If there are no other co-registrants (i.e., nciks=1), the value of aciks is NULL. For a very small number of filers, the entire list of co-registrants is too long to fit in the field. Where this is the case, users should refer to the complete submission file for all CIK information. |
| adsh | ddate | tag | value | uom | qtrs | version | segments | coreg | footnote |
|---|---|---|---|---|---|---|---|---|---|
| 0001558370-25-006966 | 20241231 | Assets Current | 54407000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001558370-25-006966 | 20241231 | Assets Current | 12957000.0000 | USD | 0 | us-gaap/2024 | Equity Method Investment Nonconsolidated Investee= Equity Method Investment Nonconsolidated Investee Or Group Of Investees; | ||
| 0001558370-25-006966 | 20240331 | Comprehensive Income Net Of Tax | -6009000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001558370-25-006966 | 20250331 | Income Loss From Equity Method Investments | -539000.0000 | USD | 1 | us-gaap/2024 | Schedule Of Equity Method Investment Equity Method Investee Name= Angel Pharmaceuticals Ltd Equity Method Investee; | ||
| 0001558370-25-006966 | 20250331 | Net Cash Provided By Used In Financing Activities | 279000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001558370-25-006966 | 20250331 | Net Income Loss | 15193000.0000 | USD | 1 | us-gaap/2024 | Equity Components= Retained Earnings; | ||
| 0001558370-25-006966 | 20240331 | Operating Income Loss | -6253000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001558370-25-006966 | 20240331 | Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax | -293000.0000 | USD | 1 | us-gaap/2024 | Equity Components= Accumulated Other Comprehensive Income; | ||
| 0001558370-25-006966 | 20240331 | Profit Loss | -5701000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001558370-25-006966 | 20240331 | Research And Development Expense | 4075000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001558370-25-006966 | 20250331 | Research And Development Expense | 94000.0000 | USD | 1 | us-gaap/2024 | Related Party Transaction= Additional Funding Agreement Terms; Related Party Transactions By Related Party= Other Affiliates; | ||
| 0001558370-25-006966 | 20241231 | Retained Earnings Accumulated Deficit | -397010000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001558370-25-006966 | 20241231 | Shares Outstanding | 67899779.0000 | shares | 0 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0001558370-25-006966 | 20231231 | Stockholders Equity | -967000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Accumulated Other Comprehensive Income; | ||
| 0001558370-25-006966 | 20241231 | Stockholders Equity | 32568000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001558370-25-006966 | 20241231 | Stockholders Equity | -397010000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Retained Earnings; | ||
| 0001558370-25-006966 | 20250331 | Stock Issued During Period Shares Stock Options Exercised | 269682.0000 | shares | 1 | us-gaap/2024 | Award Type= Employee Stock Option; Plan Name= Equity Incentive Award Plan2016; | ||
| 0001558370-25-006966 | 20250331 | Stock Issued During Period Value Stock Options Exercised | 279000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001558370-25-006966 | 20241231 | Warrants And Rights Outstanding | 28910000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001558370-25-006966 | 20241231 | Warrants And Rights Outstanding | 28910000.0000 | USD | 0 | us-gaap/2024 | Fair Value By Fair Value Hierarchy Level= Fair Value Inputs Level3; Fair Value By Measurement Frequency= Fair Value Measurements Recurring; | ||
| 0001558370-25-006966 | 20250331 | Weighted Average Number Of Diluted Shares Outstanding | 75152514.0000 | shares | 1 | us-gaap/2024 | |||
| 0001558370-25-006966 | 20250331 | Accounts Payable Current | 1308000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001558370-25-006966 | 20250331 | Accrued Liabilities Current | 3871000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001558370-25-006966 | 20241231 | Additional Paid In Capital Common Stock | 430859000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001558370-25-006966 | 20250331 | Available For Sale Securities Debt Securities | 39213000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001558370-25-006966 | 20250331 | Available For Sale Securities Debt Securities | 34404000.0000 | USD | 0 | us-gaap/2024 | Financial Instrument= U S Treasury Securities; | ||
| 0001558370-25-006966 | 20240331 | Increase Decrease In Accrued Liabilities And Other Operating Liabilities | 101000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001558370-25-006966 | 20250331 | Increase Decrease In Accrued Liabilities And Other Operating Liabilities | 146000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001558370-25-006966 | 20250331 | Increase Decrease In Other Current Assets | -3000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001558370-25-006966 | 20250331 | Investment Income Net | 525000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001558370-25-006966 | 20250331 | Liabilities | 10113000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001558370-25-006966 | 20240331 | Net Cash Provided By Used In Operating Activities | -5157000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001558370-25-006966 | 20240331 | Operating Expenses | 6253000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001558370-25-006966 | 20240331 | Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments Net Of Tax | -15000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001558370-25-006966 | 20250331 | Retained Earnings Accumulated Deficit | -381817000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001558370-25-006966 | 20240331 | Shares Outstanding | 49038582.0000 | shares | 0 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0001558370-25-006966 | 20241231 | Stockholders Equity | -1288000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Accumulated Other Comprehensive Income; | ||
| 0001558370-25-006966 | 20250331 | Stock Issued During Period Value Stock Options Exercised | 279000.0000 | USD | 1 | us-gaap/2024 | Equity Components= Additional Paid In Capital; | ||
| 0001558370-25-006966 | 20240331 | Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | 689000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001558370-25-006966 | 20240331 | Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | 689000.0000 | USD | 1 | us-gaap/2024 | Equity Components= Additional Paid In Capital; | ||
| 0001558370-25-006966 | 20250331 | Assets Current | 12232000.0000 | USD | 0 | us-gaap/2024 | Equity Method Investment Nonconsolidated Investee= Equity Method Investment Nonconsolidated Investee Or Group Of Investees; | ||
| 0001558370-25-006966 | 20241231 | Available For Sale Securities Debt Securities | 37764000.0000 | USD | 0 | us-gaap/2024 | Financial Instrument= U S Treasury Securities; | ||
| 0001558370-25-006966 | 20241231 | Common Stock Shares Issued | 67899779.0000 | shares | 0 | us-gaap/2024 | |||
| 0001558370-25-006966 | 20250331 | Common Stock Shares Outstanding | 68169461.0000 | shares | 0 | us-gaap/2024 | |||
| 0001558370-25-006966 | 20250331 | Common Stock Value | 7000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001558370-25-006966 | 20240331 | Earnings Per Share Diluted | -0.1200 | USD | 1 | us-gaap/2024 | |||
| 0001558370-25-006966 | 20240331 | Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments | -5937000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001558370-25-006966 | 20240331 | Income Loss From Equity Method Investments | 236000.0000 | USD | 1 | us-gaap/2024 | Schedule Of Equity Method Investment Equity Method Investee Name= Angel Pharmaceuticals Ltd Equity Method Investee; | ||
| 0001558370-25-006966 | 20240331 | Increase Decrease In Operating Lease Liability | -334000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001558370-25-006966 | 20240331 | Increase Decrease In Prepaid Deferred Expense And Other Assets | -84000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001558370-25-006966 | 20250331 | Increase Decrease In Prepaid Deferred Expense And Other Assets | -1168000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001558370-25-006966 | 20250331 | Liabilities Current | 9279000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001558370-25-006966 | 20240331 | Net Income Loss | -5701000.0000 | USD | 1 | us-gaap/2024 | Equity Components= Retained Earnings; | ||
| 0001558370-25-006966 | 20250331 | Operating Lease Liability Current | 319000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001558370-25-006966 | 20241231 | Operating Lease Liability Noncurrent | 937000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001558370-25-006966 | 20250331 | Operating Lease Right Of Use Asset | 1200000.0000 | USD | 0 | us-gaap/2024 | Geographical= San Francisco California Lease; | ||
| 0001558370-25-006966 | 20250331 | Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax | -23000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001558370-25-006966 | 20240331 | Payments To Acquire Available For Sale Securities Debt | 4628000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001558370-25-006966 | 20250331 | Preferred Stock Par Or Stated Value Per Share | 0.0001 | USD | 0 | us-gaap/2024 | |||
| 0001558370-25-006966 | 20250331 | Preferred Stock Shares Authorized | 10000000.0000 | shares | 0 | us-gaap/2024 | |||
| 0001558370-25-006966 | 20250331 | Preferred Stock Shares Issued | 0.0000 | shares | 0 | us-gaap/2024 | |||
| 0001558370-25-006966 | 20250331 | Preferred Stock Shares Outstanding | 0.0000 | shares | 0 | us-gaap/2024 | |||
| 0001558370-25-006966 | 20250331 | Profit Loss | 15193000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001558370-25-006966 | 20241231 | Property Plant And Equipment Net | 151000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001558370-25-006966 | 20240331 | Research And Development Expense | 27000.0000 | USD | 1 | us-gaap/2024 | Related Party Transaction= Additional Funding Agreement Terms; Related Party Transactions By Related Party= Other Affiliates; | ||
| 0001558370-25-006966 | 20250331 | Share Based Compensation | 1251000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001558370-25-006966 | 20231231 | Stockholders Equity | 5000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0001558370-25-006966 | 20241231 | Stockholders Equity | 430859000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Additional Paid In Capital; | ||
| 0001558370-25-006966 | 20250331 | Warrants And Rights Outstanding | 3781000.0000 | USD | 0 | us-gaap/2024 | Fair Value By Measurement Frequency= Fair Value Measurements Recurring; | ||
| 0001558370-25-006966 | 20240331 | Weighted Average Number Of Diluted Shares Outstanding | 49038582.0000 | shares | 1 | us-gaap/2024 | |||
| 0001558370-25-006966 | 20250331 | Weighted Average Number Of Shares Outstanding Basic | 72126496.0000 | shares | 1 | us-gaap/2024 | |||
| 0001558370-25-006966 | 20250331 | Accretion Amortization Of Discounts And Premiums Investments | 291000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001558370-25-006966 | 20250331 | Accumulated Other Comprehensive Income Loss Net Of Tax | -1254000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001558370-25-006966 | 20250331 | Additional Paid In Capital Common Stock | 432389000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001558370-25-006966 | 20250331 | Assets Current | 45491000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001558370-25-006966 | 20250331 | Common Stock Par Or Stated Value Per Share | 0.0001 | USD | 0 | us-gaap/2024 | |||
| 0001558370-25-006966 | 20241231 | Common Stock Shares Outstanding | 67899779.0000 | shares | 0 | us-gaap/2024 | |||
| 0001558370-25-006966 | 20241231 | Common Stock Value | 7000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001558370-25-006966 | 20250331 | Equity Method Investments | 12058000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001558370-25-006966 | 20250331 | Fair Value Adjustment Of Warrants | -25129000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001558370-25-006966 | 20250331 | Increase Decrease In Accounts Receivable Related Parties | 4000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001558370-25-006966 | 20240331 | Investment Income Net | 316000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001558370-25-006966 | 20250331 | Net Cash Provided By Used In Investing Activities | 4243000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001558370-25-006966 | 20240331 | Net Income Loss | -5701000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001558370-25-006966 | 20250331 | Net Income Loss | 15193000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001558370-25-006966 | 20250331 | Operating Expenses | 9922000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001558370-25-006966 | 20250331 | Operating Income Loss | -9922000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001558370-25-006966 | 20241231 | Operating Lease Right Of Use Asset | 1100000.0000 | USD | 0 | us-gaap/2024 | Geographical= San Francisco California Lease; | ||
| 0001558370-25-006966 | 20250331 | Other Assets Noncurrent | 629000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001558370-25-006966 | 20240331 | Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax | -15000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001558370-25-006966 | 20231231 | Shares Outstanding | 49038582.0000 | shares | 0 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0001558370-25-006966 | 20250331 | Shares Outstanding | 68169461.0000 | shares | 0 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0001558370-25-006966 | 20240331 | Stockholders Equity | 375052000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Additional Paid In Capital; | ||
| 0001558370-25-006966 | 20240331 | Stockholders Equity | -340418000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Retained Earnings; | ||
| 0001558370-25-006966 | 20241231 | Warrants And Rights Outstanding | 28910000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Warrant; | ||
| 0001558370-25-006966 | 20241231 | Warrants And Rights Outstanding | 28910000.0000 | USD | 0 | us-gaap/2024 | Fair Value By Measurement Frequency= Fair Value Measurements Recurring; | ||
| 0001558370-25-006966 | 20240331 | Accretion Amortization Of Discounts And Premiums Investments | 151000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001558370-25-006966 | 20241231 | Accounts Payable Current | 2582000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001558370-25-006966 | 20250331 | Accounts Receivable Net Current | 79000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001558370-25-006966 | 20241231 | Accumulated Other Comprehensive Income Loss Net Of Tax | -1288000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001558370-25-006966 | 20241231 | Available For Sale Securities Debt Securities | 43224000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001558370-25-006966 | 20241231 | Cash And Cash Equivalents At Carrying Value | 8740000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001558370-25-006966 | 20240331 | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | -5164000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001558370-25-006966 | 20240331 | Common Stock Par Or Stated Value Per Share | 0.0001 | USD | 0 | us-gaap/2024 | |||
| 0001558370-25-006966 | 20250331 | Comprehensive Income Net Of Tax | 15227000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001558370-25-006966 | 20250331 | Earnings Per Share Basic | 0.2100 | USD | 1 | us-gaap/2024 | |||
| 0001558370-25-006966 | 20250331 | General And Administrative Expense | 2469000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001558370-25-006966 | 20240331 | Increase Decrease In Other Noncurrent Assets | -284000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001558370-25-006966 | 20241231 | Liabilities | 36339000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001558370-25-006966 | 20241231 | Liabilities Current | 1202000.0000 | USD | 0 | us-gaap/2024 | Equity Method Investment Nonconsolidated Investee= Equity Method Investment Nonconsolidated Investee Or Group Of Investees; | ||
| 0001558370-25-006966 | 20240331 | Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax | -293000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001558370-25-006966 | 20250331 | Prepaid Expense And Other Assets Current | 1200000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001558370-25-006966 | 20240331 | Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities | 4621000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001558370-25-006966 | 20250331 | Research And Development Expense | 7453000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001558370-25-006966 | 20250331 | Stockholders Equity | -381817000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Retained Earnings; | ||
| 0001558370-25-006966 | 20250331 | Warrants And Rights Outstanding | 3781000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001558370-25-006966 | 20250331 | Warrants And Rights Outstanding | 3781000.0000 | USD | 0 | us-gaap/2024 | Fair Value By Fair Value Hierarchy Level= Fair Value Inputs Level3; Fair Value By Measurement Frequency= Fair Value Measurements Recurring; | ||
| 0001558370-25-006966 | 20241231 | Accounts Receivable Net Current | 75000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001558370-25-006966 | 20250331 | Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | 1251000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001558370-25-006966 | 20250331 | Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | 1251000.0000 | USD | 1 | us-gaap/2024 | Equity Components= Additional Paid In Capital; | ||
| 0001558370-25-006966 | 20241231 | Assets | 68907000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001558370-25-006966 | 20240331 | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 7456000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001558370-25-006966 | 20241231 | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 8740000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001558370-25-006966 | 20240331 | Common Stock Shares Authorized | 290000000.0000 | shares | 0 | us-gaap/2024 | |||
| 0001558370-25-006966 | 20250331 | Common Stock Shares Authorized | 290000000.0000 | shares | 0 | us-gaap/2024 | |||
| 0001558370-25-006966 | 20250331 | Common Stock Shares Issued | 68169461.0000 | shares | 0 | us-gaap/2024 | |||
| 0001558370-25-006966 | 20250331 | Earnings Per Share Diluted | -0.1300 | USD | 1 | us-gaap/2024 | |||
| 0001558370-25-006966 | 20240331 | General And Administrative Expense | 2178000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001558370-25-006966 | 20250331 | Income Loss From Equity Method Investments | -539000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001558370-25-006966 | 20250331 | Increase Decrease In Accounts Payable | -1274000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001558370-25-006966 | 20250331 | Increase Decrease In Operating Lease Liability | 31000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001558370-25-006966 | 20241231 | Liabilities Current | 35402000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001558370-25-006966 | 20250331 | Liabilities Current | 1026000.0000 | USD | 0 | us-gaap/2024 | Equity Method Investment Nonconsolidated Investee= Equity Method Investment Nonconsolidated Investee Or Group Of Investees; | ||
| 0001558370-25-006966 | 20240331 | Net Cash Provided By Used In Investing Activities | -7000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001558370-25-006966 | 20241231 | Operating Lease Liability Current | 185000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001558370-25-006966 | 20241231 | Operating Lease Right Of Use Asset | 1177000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001558370-25-006966 | 20241231 | Other Assets Noncurrent | 632000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001558370-25-006966 | 20240331 | Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments Net Of Tax | -15000.0000 | USD | 1 | us-gaap/2024 | Equity Components= Accumulated Other Comprehensive Income; | ||
| 0001558370-25-006966 | 20250331 | Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments Net Of Tax | -23000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001558370-25-006966 | 20250331 | Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax | 57000.0000 | USD | 1 | us-gaap/2024 | Equity Components= Accumulated Other Comprehensive Income; | ||
| 0001558370-25-006966 | 20151031 | Research And Development Expense | 1000000.0000 | USD | 0 | us-gaap/2024 | Counterparty Name= Vernalis R And D Limited; Research And Development Arrangement Contract To Perform For Others By Type= License Agreement Terms; | ||
| 0001558370-25-006966 | 20170430 | Research And Development Expense | 275000.0000 | USD | 0 | us-gaap/2024 | Counterparty Name= Monash License; Research And Development Arrangement Contract To Perform For Others By Type= License Agreement Terms; | ||
| 0001558370-25-006966 | 20240331 | Share Based Compensation | 689000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001558370-25-006966 | 20231231 | Stockholders Equity | 38684000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001558370-25-006966 | 20241231 | Stockholders Equity | 7000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0001558370-25-006966 | 20241231 | Stockholders Equity | 12478000.0000 | USD | 0 | us-gaap/2024 | Equity Method Investment Nonconsolidated Investee= Equity Method Investment Nonconsolidated Investee Or Group Of Investees; | ||
| 0001558370-25-006966 | 20250331 | Stockholders Equity | -1254000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Accumulated Other Comprehensive Income; | ||
| 0001558370-25-006966 | 20250331 | Available For Sale Securities Debt Securities | 4809000.0000 | USD | 0 | us-gaap/2024 | Financial Instrument= U S Government Agencies Debt Securities; | ||
| 0001558370-25-006966 | 20250331 | Cash And Cash Equivalents At Carrying Value | 4999000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001558370-25-006966 | 20250331 | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 4999000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001558370-25-006966 | 20250331 | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | -3741000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001558370-25-006966 | 20240331 | Income Loss From Equity Method Investments | 236000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001558370-25-006966 | 20241231 | Liabilities And Stockholders Equity | 68907000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001558370-25-006966 | 20250331 | Liabilities And Stockholders Equity | 59438000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001558370-25-006966 | 20250331 | Operating Lease Liability Noncurrent | 834000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001558370-25-006966 | 20250331 | Operating Lease Right Of Use Asset | 1095000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001558370-25-006966 | 20250331 | Payments To Acquire Property Plant And Equipment | 36000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001558370-25-006966 | 20240331 | Preferred Stock Par Or Stated Value Per Share | 0.0001 | USD | 0 | us-gaap/2024 | |||
| 0001558370-25-006966 | 20240331 | Preferred Stock Shares Authorized | 10000000.0000 | shares | 0 | us-gaap/2024 | |||
| 0001558370-25-006966 | 20240331 | Preferred Stock Shares Issued | 0.0000 | shares | 0 | us-gaap/2024 | |||
| 0001558370-25-006966 | 20240331 | Preferred Stock Shares Outstanding | 0.0000 | shares | 0 | us-gaap/2024 | |||
| 0001558370-25-006966 | 20241231 | Prepaid Expense And Other Assets Current | 2368000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001558370-25-006966 | 20250331 | Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities | 11987000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001558370-25-006966 | 20151231 | Research And Development Expense | 10000.0000 | USD | 4 | us-gaap/2024 | Counterparty Name= Scripps Research Institute; Research And Development Arrangement Contract To Perform For Others By Type= License Agreement Terms; | ||
| 0001558370-25-006966 | 20231231 | Stockholders Equity | 374363000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Additional Paid In Capital; | ||
| 0001558370-25-006966 | 20240331 | Stockholders Equity | -1275000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Accumulated Other Comprehensive Income; | ||
| 0001558370-25-006966 | 20240331 | Stockholders Equity | 5000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0001558370-25-006966 | 20250331 | Stockholders Equity | 49325000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001558370-25-006966 | 20250331 | Stockholders Equity | 432389000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Additional Paid In Capital; | ||
| 0001558370-25-006966 | 20250331 | Stockholders Equity | 7000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0001558370-25-006966 | 20250331 | Stockholders Equity | 11912000.0000 | USD | 0 | us-gaap/2024 | Equity Method Investment Nonconsolidated Investee= Equity Method Investment Nonconsolidated Investee Or Group Of Investees; | ||
| 0001558370-25-006966 | 20250331 | Stock Issued During Period Shares Stock Options Exercised | 269682.0000 | shares | 1 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0001558370-25-006966 | 20240331 | Weighted Average Number Of Shares Outstanding Basic | 49038582.0000 | shares | 1 | us-gaap/2024 | |||
| 0001558370-25-006966 | 20241231 | Accrued Liabilities Current | 3725000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001558370-25-006966 | 20250331 | Assets | 59438000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001558370-25-006966 | 20241231 | Available For Sale Securities Debt Securities | 5460000.0000 | USD | 0 | us-gaap/2024 | Financial Instrument= U S Government Agencies Debt Securities; | ||
| 0001558370-25-006966 | 20231231 | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 12620000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001558370-25-006966 | 20240331 | Depreciation Depletion And Amortization | 23000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001558370-25-006966 | 20250331 | Depreciation Depletion And Amortization | 22000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001558370-25-006966 | 20240331 | Earnings Per Share Basic | -0.1200 | USD | 1 | us-gaap/2024 | |||
| 0001558370-25-006966 | 20241231 | Equity Method Investments | 12540000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001558370-25-006966 | 20250331 | Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments | 15732000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001558370-25-006966 | 20240331 | Increase Decrease In Accounts Payable | 84000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001558370-25-006966 | 20250331 | Increase Decrease In Other Noncurrent Assets | -82000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001558370-25-006966 | 20250331 | Net Cash Provided By Used In Operating Activities | -8263000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001558370-25-006966 | 20250331 | Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments Net Of Tax | -23000.0000 | USD | 1 | us-gaap/2024 | Equity Components= Accumulated Other Comprehensive Income; | ||
| 0001558370-25-006966 | 20250331 | Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax | 57000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001558370-25-006966 | 20250331 | Payments To Acquire Available For Sale Securities Debt | 7708000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001558370-25-006966 | 20250331 | Proceeds From Stock Options Exercised | 279000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001558370-25-006966 | 20250331 | Property Plant And Equipment Net | 165000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001558370-25-006966 | 20231231 | Stockholders Equity | -334717000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Retained Earnings; | ||
| 0001558370-25-006966 | 20240331 | Stockholders Equity | 33364000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001558370-25-006966 | 20250331 | Warrants And Rights Outstanding | 3781000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Warrant; |
| Field Name | Field Description |
|---|---|
| adsh | Accession Number. The 20-character string formed from the 18-digit number assigned by the SEC to each EDGAR submission. |
| tag | The unique identifier (name) for a tag in a specific taxonomy release. |
| version | For a standard tag, an identifier for the taxonomy; otherwise the accession number where the tag was defined. |
| ddate | The end date for the data value, rounded to the nearest month end. |
| qtrs | The count of the number of quarters represented by the data value, rounded to the nearest whole number. “0” indicates it is a point-in-time value. |
| uom | The unit of measure for the value. |
| segments | Tags used to represent axis and member reporting. |
| coreg | If specified, indicates a specific co-registrant, the parent company, or other entity (e.g., guarantor). NULL indicates the consolidated entity. |
| value | The value. This is not scaled, it is as found in the Interactive Data file, but is limited to four digits to the right of the decimal point. |
| footnote | The text of any superscripted footnotes on the value, as shown on the statement page, truncated to 512 characters, or if there is no footnote, then this field will be blank. |
| tag | version | custom | abstract | datatype | iord | crdr | tlabel | doc |
|---|---|---|---|---|---|---|---|---|
| Stock Issued During Period Value Stock Options Exercised | us-gaap/2024 | 0 | 0 | monetary | D | C | Stock Issued During Period, Value, Stock Options Exercised | Value of stock issued as a result of the exercise of stock options. |
| Assets Current | us-gaap/2024 | 0 | 0 | monetary | I | D | Assets, Current | Amount of asset recognized for present right to economic benefit, classified as current. |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | us-gaap/2024 | 0 | 0 | monetary | I | D | Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents | Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. |
| Increase Decrease In Other Noncurrent Assets | us-gaap/2024 | 0 | 0 | monetary | D | C | Increase (Decrease) in Other Noncurrent Assets | Amount of increase (decrease) in noncurrent assets classified as other. |
| Operating Lease Liability Current | us-gaap/2024 | 0 | 0 | monetary | I | C | Operating Lease, Liability, Current | Present value of lessee's discounted obligation for lease payments from operating lease, classified as current. |
| Payments To Acquire Property Plant And Equipment | us-gaap/2024 | 0 | 0 | monetary | D | C | Payments to Acquire Property, Plant, and Equipment | The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets. |
| Comprehensive Income Net Of Tax | us-gaap/2024 | 0 | 0 | monetary | D | C | Comprehensive Income (Loss), Net of Tax, Attributable to Parent | Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners. |
| Liabilities | us-gaap/2024 | 0 | 0 | monetary | I | C | Liabilities | Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others. |
| Liabilities And Stockholders Equity | us-gaap/2024 | 0 | 0 | monetary | I | C | Liabilities and Equity | Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any. |
| Proceeds From Stock Options Exercised | us-gaap/2024 | 0 | 0 | monetary | D | D | Proceeds from Stock Options Exercised | Amount of cash inflow from exercise of option under share-based payment arrangement. |
| Retained Earnings Accumulated Deficit | us-gaap/2024 | 0 | 0 | monetary | I | C | Retained Earnings (Accumulated Deficit) | Amount of accumulated undistributed earnings (deficit). |
| Accounts Receivable Net Current | us-gaap/2024 | 0 | 0 | monetary | I | D | Accounts Receivable, after Allowance for Credit Loss, Current | Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current. |
| Available For Sale Securities Debt Securities | us-gaap/2024 | 0 | 0 | monetary | I | D | Debt Securities, Available-for-Sale | Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). |
| Common Stock Par Or Stated Value Per Share | us-gaap/2024 | 0 | 0 | perShare | I | Common Stock, Par or Stated Value Per Share | Face amount or stated value per share of common stock. | |
| Common Stock Shares Outstanding | us-gaap/2024 | 0 | 0 | shares | I | Common Stock, Shares, Outstanding | Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation. | |
| Net Income Loss | us-gaap/2024 | 0 | 0 | monetary | D | C | Net Income (Loss) Attributable to Parent | The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. |
| Stockholders Equity | us-gaap/2024 | 0 | 0 | monetary | I | C | Equity, Attributable to Parent | Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. |
| Weighted Average Number Of Diluted Shares Outstanding | us-gaap/2024 | 0 | 0 | shares | D | Weighted Average Number of Shares Outstanding, Diluted | The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. | |
| Accrued Liabilities Current | us-gaap/2024 | 0 | 0 | monetary | I | C | Accrued Liabilities, Current | Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). |
| Accumulated Other Comprehensive Income Loss Net Of Tax | us-gaap/2024 | 0 | 0 | monetary | I | C | Accumulated Other Comprehensive Income (Loss), Net of Tax | Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source. |
| Assets | us-gaap/2024 | 0 | 0 | monetary | I | D | Assets | Amount of asset recognized for present right to economic benefit. |
| Common Stock Shares Issued | us-gaap/2024 | 0 | 0 | shares | I | Common Stock, Shares, Issued | Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. | |
| Earnings Per Share Diluted | us-gaap/2024 | 0 | 0 | perShare | D | Earnings Per Share, Diluted | The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. | |
| Operating Lease Right Of Use Asset | us-gaap/2024 | 0 | 0 | monetary | I | D | Operating Lease, Right-of-Use Asset | Amount of lessee's right to use underlying asset under operating lease. |
| Other Assets Noncurrent | us-gaap/2024 | 0 | 0 | monetary | I | D | Other Assets, Noncurrent | Amount of noncurrent assets classified as other. |
| Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments Net Of Tax | us-gaap/2024 | 0 | 0 | monetary | D | C | OCI, Debt Securities, Available-for-Sale, Gain (Loss), before Adjustment, after Tax | Amount, after tax and before adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale. |
| Depreciation Depletion And Amortization | us-gaap/2024 | 0 | 0 | monetary | D | D | Depreciation, Depletion and Amortization | The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets. |
| Liabilities Current | us-gaap/2024 | 0 | 0 | monetary | I | C | Liabilities, Current | Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. |
| Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax | us-gaap/2024 | 0 | 0 | monetary | D | C | Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax | Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature. |
| Payments To Acquire Available For Sale Securities Debt | us-gaap/2024 | 0 | 0 | monetary | D | C | Payments to Acquire Debt Securities, Available-for-Sale | Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). |
| Preferred Stock Shares Issued | us-gaap/2024 | 0 | 0 | shares | I | Preferred Stock, Shares Issued | Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt. | |
| Share Based Compensation | us-gaap/2024 | 0 | 0 | monetary | D | D | Share-Based Payment Arrangement, Noncash Expense | Amount of noncash expense for share-based payment arrangement. |
| Cash And Cash Equivalents At Carrying Value | us-gaap/2024 | 0 | 0 | monetary | I | D | Cash and Cash Equivalents, at Carrying Value | Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. |
| Equity Method Investments | us-gaap/2024 | 0 | 0 | monetary | I | D | Equity Method Investments | This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized. |
| Increase Decrease In Prepaid Deferred Expense And Other Assets | us-gaap/2024 | 0 | 0 | monetary | D | C | Increase (Decrease) in Prepaid Expense and Other Assets | Amount of increase (decrease) in prepaid expenses, and assets classified as other. |
| Profit Loss | us-gaap/2024 | 0 | 0 | monetary | D | C | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest | The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest. |
| Warrants And Rights Outstanding | us-gaap/2024 | 0 | 0 | monetary | I | C | Warrants and Rights Outstanding | Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price. |
| Increase Decrease In Accrued Liabilities And Other Operating Liabilities | us-gaap/2024 | 0 | 0 | monetary | D | D | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities | Amount of increase (decrease) in accrued expenses, and obligations classified as other. |
| Net Cash Provided By Used In Operating Activities | us-gaap/2024 | 0 | 0 | monetary | D | Net Cash Provided by (Used in) Operating Activities | Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. | |
| Operating Expenses | us-gaap/2024 | 0 | 0 | monetary | D | D | Operating Expenses | Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense. |
| Operating Income Loss | us-gaap/2024 | 0 | 0 | monetary | D | C | Operating Income (Loss) | The net result for the period of deducting operating expenses from operating revenues. |
| Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax | us-gaap/2024 | 0 | 0 | monetary | D | C | OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax | Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale. |
| Accounts Payable Current | us-gaap/2024 | 0 | 0 | monetary | I | C | Accounts Payable, Current | Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). |
| Prepaid Expense And Other Assets Current | us-gaap/2024 | 0 | 0 | monetary | I | D | Prepaid Expense and Other Assets, Current | Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer. |
| Common Stock Value | us-gaap/2024 | 0 | 0 | monetary | I | C | Common Stock, Value, Issued | Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity. |
| General And Administrative Expense | us-gaap/2024 | 0 | 0 | monetary | D | D | General and Administrative Expense | The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line. |
| Income Loss From Equity Method Investments | us-gaap/2024 | 0 | 0 | monetary | D | C | Income (Loss) from Equity Method Investments | Amount of income (loss) for proportionate share of equity method investee's income (loss). |
| Increase Decrease In Other Current Assets | us-gaap/2024 | 0 | 0 | monetary | D | C | Increase (Decrease) in Other Current Assets | Amount of increase (decrease) in current assets classified as other. |
| Research And Development Expense | us-gaap/2024 | 0 | 0 | monetary | D | D | Research and Development Expense | Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. |
| Additional Paid In Capital Common Stock | us-gaap/2024 | 0 | 0 | monetary | I | C | Additional Paid in Capital, Common Stock | Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital. |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | us-gaap/2024 | 0 | 0 | monetary | D | D | Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect | Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. |
| Common Stock Shares Authorized | us-gaap/2024 | 0 | 0 | shares | I | Common Stock, Shares Authorized | The maximum number of common shares permitted to be issued by an entity's charter and bylaws. | |
| Fair Value Adjustment Of Warrants | us-gaap/2024 | 0 | 0 | monetary | D | D | Fair Value Adjustment of Warrants | Amount of expense (income) related to adjustment to fair value of warrant liability. |
| Increase Decrease In Accounts Payable | us-gaap/2024 | 0 | 0 | monetary | D | D | Increase (Decrease) in Accounts Payable | The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. |
| Increase Decrease In Accounts Receivable Related Parties | us-gaap/2024 | 0 | 0 | monetary | D | C | Increase (Decrease) in Accounts Receivable, Related Parties | The increase (decrease) during the reporting period in the amount due to the reporting entity for good and services provided to the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management, an entity and its principal owners, management, member of their immediate families, affiliates, or other parties with the ability to exert significant influence. |
| Increase Decrease In Operating Lease Liability | us-gaap/2024 | 0 | 0 | monetary | D | D | Increase (Decrease) in Operating Lease Liability | Amount of increase (decrease) in obligation for operating lease. |
| Investment Income Net | us-gaap/2024 | 0 | 0 | monetary | D | C | Investment Income, Net | Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities. |
| Net Cash Provided By Used In Financing Activities | us-gaap/2024 | 0 | 0 | monetary | D | D | Net Cash Provided by (Used in) Financing Activities | Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit. |
| Preferred Stock Par Or Stated Value Per Share | us-gaap/2024 | 0 | 0 | perShare | I | Preferred Stock, Par or Stated Value Per Share | Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer. | |
| Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities | us-gaap/2024 | 0 | 0 | monetary | D | D | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale | Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). |
| Shares Outstanding | us-gaap/2024 | 0 | 0 | shares | I | Shares, Outstanding | Number of shares issued which are neither cancelled nor held in the treasury. | |
| Accretion Amortization Of Discounts And Premiums Investments | us-gaap/2024 | 0 | 0 | monetary | D | C | Accretion (Amortization) of Discounts and Premiums, Investments | The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method. |
| Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | us-gaap/2024 | 0 | 0 | monetary | D | C | APIC, Share-Based Payment Arrangement, Increase for Cost Recognition | Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement. |
| Earnings Per Share Basic | us-gaap/2024 | 0 | 0 | perShare | D | Earnings Per Share, Basic | The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. | |
| Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments | us-gaap/2024 | 0 | 0 | monetary | D | C | Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest | Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments. |
| Net Cash Provided By Used In Investing Activities | us-gaap/2024 | 0 | 0 | monetary | D | D | Net Cash Provided by (Used in) Investing Activities | Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets. |
| Preferred Stock Shares Authorized | us-gaap/2024 | 0 | 0 | shares | I | Preferred Stock, Shares Authorized | The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws. | |
| Preferred Stock Shares Outstanding | us-gaap/2024 | 0 | 0 | shares | I | Preferred Stock, Shares Outstanding | Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased. | |
| Stock Issued During Period Shares Stock Options Exercised | us-gaap/2024 | 0 | 0 | shares | D | Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period | Number of share options (or share units) exercised during the current period. | |
| Operating Lease Liability Noncurrent | us-gaap/2024 | 0 | 0 | monetary | I | C | Operating Lease, Liability, Noncurrent | Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent. |
| Property Plant And Equipment Net | us-gaap/2024 | 0 | 0 | monetary | I | D | Property, Plant and Equipment, Net | Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. |
| Weighted Average Number Of Shares Outstanding Basic | us-gaap/2024 | 0 | 0 | shares | D | Weighted Average Number of Shares Outstanding, Basic | Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. |
| Field Name | Field Description |
|---|---|
| tag | The unique identifier (name) for a tag in a specific taxonomy release. |
| version | For a standard tag, an identifier for the taxonomy; otherwise the accession number where the tag was defined. |
| custom | 1 if tag is custom (version=adsh), 0 if it is standard. Note: This flag is technically redundant with the version and adsh columns. |
| abstract | 1 if the tag is not used to represent a numeric fact. |
| datatype | If abstract=1, then NULL, otherwise the data type (e.g., monetary) for the tag. |
| iord | If abstract=1, then NULL; otherwise, “I” if the value is a point-in time, or “D” if the value is a duration. |
| crdr | If datatype = monetary, then the tag’s natural accounting balance (debit or credit); if not defined, then NULL. |
| tlabel | If a standard tag, then the label text provided by the taxonomy, otherwise the text provided by the filer. A tag which had neither would have a NULL value here. |
| doc | The detailed definition for the tag. If a standard tag, then the text provided by the taxonomy, otherwise the text assigned by the filer. Some tags have neither, and this field is NULL. |
| adsh | report | line | stmt | inpth | rfile | tag | version | plabel | negating |
|---|---|---|---|---|---|---|---|---|---|
| 0001558370-25-006966 | 2 | 3 | BS | 0 | H | Cash And Cash Equivalents At Carrying Value | us-gaap/2024 | Cash and cash equivalents | 0 |
| 0001558370-25-006966 | 2 | 4 | BS | 0 | H | Available For Sale Securities Debt Securities | us-gaap/2024 | Marketable securities | 0 |
| 0001558370-25-006966 | 2 | 5 | BS | 0 | H | Accounts Receivable Net Current | us-gaap/2024 | Accounts receivable - related party | 0 |
| 0001558370-25-006966 | 2 | 6 | BS | 0 | H | Prepaid Expense And Other Assets Current | us-gaap/2024 | Prepaid and other current assets | 0 |
| 0001558370-25-006966 | 2 | 7 | BS | 0 | H | Assets Current | us-gaap/2024 | Total current assets | 0 |
| 0001558370-25-006966 | 2 | 8 | BS | 0 | H | Property Plant And Equipment Net | us-gaap/2024 | Property and equipment, net | 0 |
| 0001558370-25-006966 | 2 | 9 | BS | 0 | H | Operating Lease Right Of Use Asset | us-gaap/2024 | Operating lease right-of-use asset | 0 |
| 0001558370-25-006966 | 2 | 10 | BS | 0 | H | Equity Method Investments | us-gaap/2024 | Investment in Angel Pharmaceuticals | 0 |
| 0001558370-25-006966 | 2 | 11 | BS | 0 | H | Other Assets Noncurrent | us-gaap/2024 | Other assets | 0 |
| 0001558370-25-006966 | 2 | 12 | BS | 0 | H | Assets | us-gaap/2024 | Total assets | 0 |
| 0001558370-25-006966 | 2 | 15 | BS | 0 | H | Accounts Payable Current | us-gaap/2024 | Accounts payable | 0 |
| 0001558370-25-006966 | 2 | 16 | BS | 0 | H | Operating Lease Liability Current | us-gaap/2024 | Operating lease liability | 0 |
| 0001558370-25-006966 | 2 | 17 | BS | 0 | H | Accrued Liabilities Current | us-gaap/2024 | Accrued and other liabilities | 0 |
| 0001558370-25-006966 | 2 | 18 | BS | 0 | H | Warrants And Rights Outstanding | us-gaap/2024 | Warrant liability | 0 |
| 0001558370-25-006966 | 2 | 19 | BS | 0 | H | Liabilities Current | us-gaap/2024 | Total current liabilities | 0 |
| 0001558370-25-006966 | 2 | 20 | BS | 0 | H | Operating Lease Liability Noncurrent | us-gaap/2024 | Operating lease liability | 0 |
| 0001558370-25-006966 | 2 | 21 | BS | 0 | H | Liabilities | us-gaap/2024 | Total liabilities | 0 |
| 0001558370-25-006966 | 2 | 23 | BS | 0 | H | Common Stock Value | us-gaap/2024 | Common stock: $0.0001 par value; 290,000,000 shares authorized at March 31, 2025 and December 31, 2024; 68,169,461 and 67,899,779 shares issued and outstanding at March 31, 2025 and December 31, 2024 | 0 |
| 0001558370-25-006966 | 2 | 24 | BS | 0 | H | Additional Paid In Capital Common Stock | us-gaap/2024 | Additional paid-in capital | 0 |
| 0001558370-25-006966 | 2 | 25 | BS | 0 | H | Accumulated Other Comprehensive Income Loss Net Of Tax | us-gaap/2024 | Accumulated other comprehensive loss | 0 |
| 0001558370-25-006966 | 2 | 26 | BS | 0 | H | Retained Earnings Accumulated Deficit | us-gaap/2024 | Accumulated deficit | 0 |
| 0001558370-25-006966 | 2 | 27 | BS | 0 | H | Stockholders Equity | us-gaap/2024 | Total stockholders' equity | 0 |
| 0001558370-25-006966 | 2 | 28 | BS | 0 | H | Liabilities And Stockholders Equity | us-gaap/2024 | Total liabilities and stockholders' equity | 0 |
| 0001558370-25-006966 | 3 | 1 | BS | 1 | H | Preferred Stock Par Or Stated Value Per Share | us-gaap/2024 | Preferred stock, par value (in dollars per share) | 0 |
| 0001558370-25-006966 | 3 | 2 | BS | 1 | H | Preferred Stock Shares Authorized | us-gaap/2024 | Preferred stock, shares authorized | 0 |
| 0001558370-25-006966 | 3 | 3 | BS | 1 | H | Preferred Stock Shares Issued | us-gaap/2024 | Preferred stock, shares issued | 0 |
| 0001558370-25-006966 | 3 | 4 | BS | 1 | H | Preferred Stock Shares Outstanding | us-gaap/2024 | Preferred stock, shares outstanding | 0 |
| 0001558370-25-006966 | 3 | 5 | BS | 1 | H | Common Stock Par Or Stated Value Per Share | us-gaap/2024 | Common stock, par value (in dollars per share) | 0 |
| 0001558370-25-006966 | 3 | 6 | BS | 1 | H | Common Stock Shares Authorized | us-gaap/2024 | Common stock, shares authorized | 0 |
| 0001558370-25-006966 | 3 | 7 | BS | 1 | H | Common Stock Shares Issued | us-gaap/2024 | Common stock, shares issued | 0 |
| 0001558370-25-006966 | 3 | 8 | BS | 1 | H | Common Stock Shares Outstanding | us-gaap/2024 | Common stock, shares outstanding | 0 |
| 0001558370-25-006966 | 4 | 2 | IS | 0 | H | Research And Development Expense | us-gaap/2024 | Research and development | 0 |
| 0001558370-25-006966 | 4 | 3 | IS | 0 | H | General And Administrative Expense | us-gaap/2024 | General and administrative | 0 |
| 0001558370-25-006966 | 4 | 4 | IS | 0 | H | Operating Expenses | us-gaap/2024 | Total operating expenses | 0 |
| 0001558370-25-006966 | 4 | 5 | IS | 0 | H | Operating Income Loss | us-gaap/2024 | Loss from operations | 0 |
| 0001558370-25-006966 | 4 | 6 | IS | 0 | H | Investment Income Net | us-gaap/2024 | Interest income and other expense, net | 0 |
| 0001558370-25-006966 | 4 | 7 | IS | 0 | H | Fair Value Adjustment Of Warrants | us-gaap/2024 | Change in fair value of warrant liability | 1 |
| 0001558370-25-006966 | 4 | 8 | IS | 0 | H | Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments | us-gaap/2024 | Income (loss) before equity method investment | 0 |
| 0001558370-25-006966 | 4 | 9 | IS | 0 | H | Income Loss From Equity Method Investments | us-gaap/2024 | Income (loss) from equity method investment | 0 |
| 0001558370-25-006966 | 4 | 10 | IS | 0 | H | Net Income Loss | us-gaap/2024 | Net income (loss) | 0 |
| 0001558370-25-006966 | 4 | 11 | IS | 0 | H | Earnings Per Share Basic | us-gaap/2024 | Net income (loss) per share, basic | 0 |
| 0001558370-25-006966 | 4 | 12 | IS | 0 | H | Earnings Per Share Diluted | us-gaap/2024 | Net loss per share, diluted | 0 |
| 0001558370-25-006966 | 4 | 13 | IS | 0 | H | Weighted Average Number Of Shares Outstanding Basic | us-gaap/2024 | Shares used to compute net income (loss) per share, basic | 0 |
| 0001558370-25-006966 | 4 | 14 | IS | 0 | H | Weighted Average Number Of Diluted Shares Outstanding | us-gaap/2024 | Shares used to compute net loss per share, diluted | 0 |
| 0001558370-25-006966 | 4 | 16 | IS | 0 | H | Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax | us-gaap/2024 | Unrealized loss on marketable securities | 0 |
| 0001558370-25-006966 | 4 | 17 | IS | 0 | H | Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax | us-gaap/2024 | Cumulative foreign currency translation adjustment | 0 |
| 0001558370-25-006966 | 4 | 18 | IS | 0 | H | Comprehensive Income Net Of Tax | us-gaap/2024 | Comprehensive income (loss) | 0 |
| 0001558370-25-006966 | 5 | 9 | EQ | 0 | H | Stockholders Equity | us-gaap/2024 | Balance | 0 |
| 0001558370-25-006966 | 5 | 10 | EQ | 0 | H | Shares Outstanding | us-gaap/2024 | Balance (in shares) | 0 |
| 0001558370-25-006966 | 5 | 12 | EQ | 0 | H | Stock Issued During Period Value Stock Options Exercised | us-gaap/2024 | Common stock issued on exercise of stock options | 0 |
| 0001558370-25-006966 | 5 | 13 | EQ | 0 | H | Stock Issued During Period Shares Stock Options Exercised | us-gaap/2024 | Common stock issued on exercise of stock options (in shares) | 0 |
| 0001558370-25-006966 | 5 | 14 | EQ | 0 | H | Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | us-gaap/2024 | Stock-based compensation expense | 0 |
| 0001558370-25-006966 | 5 | 15 | EQ | 0 | H | Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments Net Of Tax | us-gaap/2024 | Unrealized loss on marketable securities | 0 |
| 0001558370-25-006966 | 5 | 16 | EQ | 0 | H | Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax | us-gaap/2024 | Foreign currency translation adjustment | 0 |
| 0001558370-25-006966 | 5 | 17 | EQ | 0 | H | Net Income Loss | us-gaap/2024 | Net Income (Loss) | 0 |
| 0001558370-25-006966 | 5 | 18 | EQ | 0 | H | Stockholders Equity | us-gaap/2024 | Balance | 0 |
| 0001558370-25-006966 | 5 | 19 | EQ | 0 | H | Shares Outstanding | us-gaap/2024 | Balance (in shares) | 0 |
| 0001558370-25-006966 | 6 | 2 | CF | 0 | H | Profit Loss | us-gaap/2024 | Net income (loss) | 0 |
| 0001558370-25-006966 | 6 | 4 | CF | 0 | H | Depreciation Depletion And Amortization | us-gaap/2024 | Depreciation and amortization | 0 |
| 0001558370-25-006966 | 6 | 5 | CF | 0 | H | Accretion Amortization Of Discounts And Premiums Investments | us-gaap/2024 | Accretion related to marketable securities | 1 |
| 0001558370-25-006966 | 6 | 6 | CF | 0 | H | Share Based Compensation | us-gaap/2024 | Stock-based compensation | 0 |
| 0001558370-25-006966 | 6 | 7 | CF | 0 | H | Fair Value Adjustment Of Warrants | us-gaap/2024 | Change in fair value of warrant liability | 0 |
| 0001558370-25-006966 | 6 | 8 | CF | 0 | H | Income Loss From Equity Method Investments | us-gaap/2024 | Loss (gain) from equity method investment | 1 |
| 0001558370-25-006966 | 6 | 10 | CF | 0 | H | Increase Decrease In Accounts Receivable Related Parties | us-gaap/2024 | Accounts receivable - related party | 1 |
| 0001558370-25-006966 | 6 | 11 | CF | 0 | H | Increase Decrease In Prepaid Deferred Expense And Other Assets | us-gaap/2024 | Prepaid and other current assets | 1 |
| 0001558370-25-006966 | 6 | 12 | CF | 0 | H | Increase Decrease In Other Noncurrent Assets | us-gaap/2024 | Operating lease right-of-use assets | 1 |
| 0001558370-25-006966 | 6 | 13 | CF | 0 | H | Increase Decrease In Other Current Assets | us-gaap/2024 | Other assets | 1 |
| 0001558370-25-006966 | 6 | 14 | CF | 0 | H | Increase Decrease In Accounts Payable | us-gaap/2024 | Accounts payable | 0 |
| 0001558370-25-006966 | 6 | 15 | CF | 0 | H | Increase Decrease In Accrued Liabilities And Other Operating Liabilities | us-gaap/2024 | Accrued and other liabilities | 0 |
| 0001558370-25-006966 | 6 | 16 | CF | 0 | H | Increase Decrease In Operating Lease Liability | us-gaap/2024 | Operating lease liability | 0 |
| 0001558370-25-006966 | 6 | 17 | CF | 0 | H | Net Cash Provided By Used In Operating Activities | us-gaap/2024 | Net cash used in operating activities | 0 |
| 0001558370-25-006966 | 6 | 19 | CF | 0 | H | Payments To Acquire Available For Sale Securities Debt | us-gaap/2024 | Purchases of marketable securities | 1 |
| 0001558370-25-006966 | 6 | 20 | CF | 0 | H | Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities | us-gaap/2024 | Maturities of marketable securities | 0 |
| 0001558370-25-006966 | 6 | 21 | CF | 0 | H | Payments To Acquire Property Plant And Equipment | us-gaap/2024 | Purchases of property and equipment | 1 |
| 0001558370-25-006966 | 6 | 22 | CF | 0 | H | Net Cash Provided By Used In Investing Activities | us-gaap/2024 | Net cash (used in) provided by investing activities | 0 |
| 0001558370-25-006966 | 6 | 24 | CF | 0 | H | Proceeds From Stock Options Exercised | us-gaap/2024 | Proceeds from exercise of common stock options | 0 |
| 0001558370-25-006966 | 6 | 25 | CF | 0 | H | Net Cash Provided By Used In Financing Activities | us-gaap/2024 | Net cash provided by financing activities | 0 |
| 0001558370-25-006966 | 6 | 26 | CF | 0 | H | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | us-gaap/2024 | Net decrease in cash and cash equivalents | 0 |
| 0001558370-25-006966 | 6 | 27 | CF | 0 | H | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | us-gaap/2024 | Cash and cash equivalents at beginning of the period | 0 |
| 0001558370-25-006966 | 6 | 28 | CF | 0 | H | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | us-gaap/2024 | Cash and cash equivalents at end of the period | 0 |
| Field Name | Field Description |
|---|---|
| adsh | Accession Number. The 20-character string formed from the 18-digit number assigned by the SEC to each EDGAR submission. |
| report | Represents the report grouping. This field corresponds to the statement (stmt) field, which indicates the type of statement. The numeric value refers to the “R file” as posted on the EDGAR Web site. |
| line | Represents the tag’s presentation line order for a given report. Together with the statement and report field, presentation location, order and grouping can be derived. |
| stmt | The financial statement location to which the value of the “report” field pertains. |
| inpth | Value was presented “parenthetically” instead of in columns within the financial statements. For example: Receivables (net of allowance for bad debts of $200 in 2012) $700. |
| rfile | The type of interactive data file rendered on the EDGAR web site, H = .htm file, X = .xml file. |
| tag | The tag chosen by the filer for this line item. |
| version | The taxonomy identifier if the tag is a standard tag, otherwise adsh. |
| plabel | The text presented on the line item, also known as a “preferred” label. |
| negating | Flag to indicate whether the plabel is negating. |